Wednesday, 28 Jun 2017

News

Steroid Injections for Knee Osteoarthritis May Promote Cartilage Loss

Treatment of knee osteoarthritis (with synovitis) with an injection of a corticosteroid every three months over two years resulted in significantly greater cartilage volume loss and no significant difference in knee pain compared to patients who received a placebo injection, according to a study published by JAMA.

No Arthroscopy Needed for Degenerative Knees and Meniscal Tears

The British Medical Journal has published a clinical practice guideline for the use of arthroscopic surgery for degenerative knee arthritis and meniscal tears, suggesting that many patients will not benefit from such surgery. (Citation source http://buff.ly/2pNhgug)

Rituximab May Benefit Rheumatoid Lung

A retrospective study shows that rituximab treatment of RA-related interstitial lung disease may improve or forestall ILD progression.

The RheumNow Week in Review – 12 May 2017

Dr. Jack Cush highlights the big stories, news and articles from this week at RheumNow.com.

Adalimumab Effective in Pediatric Plaque Psoriasis

Adalimumab is currently FDA approved for use in adult psoriasis, pediatric Crohn's disease and polyarticular juvenile idiopathic arthritis.  The current Lancet trial assesses the efficacy and safety of adalimumab in children and adolescents with severe plaque psoriasis.

NSAIDs Increase Risk of Acute Myocardial Infarction

Using data from Canadian and European healthcare databases, the BMJ has reported that all NSAIDs, including celecoxib and naproxen, increase the risk of acute myocardial infarction.

While the recent 24,081 patient PRECISION study showed noninferiority between celecoxib, naproxen and ibuprofen with regard to CV risk, that study did not include a placebo arm.

One-Third of FDA Approvals Need Post-Marketing Safety Changes

One-third of newly approved drugs in the next decade will require new safety warnings based on pharmacovigilance, according to a new study in JAMA. (Citation Source: http://buff.ly/2r3dYUs)

An analysis by the Food and Drug Administration (FDA), looked at all 222 prescription drugs (183 pharmaceuticals and 39 biologics) approved between 2001 through 2010.

High Mortality with ANCA Associated Vasculitis

Mortality remains high in patients with the types of vasculitis that are associated with the presence of antineutrophil cytoplasmic antibodies (ANCA), a meta-analysis in Annals of the Rheumatic Diseases determined.

Above-Label Dosing and Noncompliance with Biologics in Psoriatic Arthritis

Claims data analysis of 4245 psoriatic arthritis patients on TNF inhibitors showed both higher than expected durations of noncompliance and higher than label dosing - all at an increased cost.

ACP Guideline Recommends Generic Bisphosphonates But Limits DEXA Use

The American College of Physicians (ACP) has updated its 2008 clincial practice guideline on the treatment of low bone density and osteoporosis to prevent fractures in men and women.  The new guideline is in favor of generic bisphosphonate use and recommends against using menopausal estrogen therapy and against DEXA monitoring during the first 5 years.

CDC Shows a 40% Lifetime Risk of Symptomatic Hand Osteoarthritis

Qin and colleagues have published in Arthritis & Rheumatology that 40% of people will be affected by symptomatic osteoarthritis in at least one hand.  (Citation source: http://buff.ly/2qTUscZ)  

Calcium Supplements and Cardiovascular Risk

Dr. Nancy Lane answers questions about the intake of Calcium, Vitamin D and the cardiovascular risk of supplemental calcium.